The Pattern of Proinflamatory Cytokine Expression By CD4+ T Lymphocytes Segregates the Clinical Response to Methotrexate in Recently Diagnosed Rheumatoid Arthritis Patients
- Jorge Monserrat Sanz 1
- Ana Maria Gómez Lahoz 1
- Cristina Bohórquez Heras 2
- Maria Dolores Sosa Reina 1
- Atusa Movasat 2
- Ana Pérez Gómez 2
- Lucía Ruiz Gutiérrez 2
- Ana Sánchez Atrio 2
- Eduardo Cuende Quintana 2
- Maria José León 2
- David Diaz 1
- Fernando Albarrán Hernández 2
- Melchor Alvarez-Mon 12
-
1
Universidad de Alcalá
info
-
2
Hospital Universitario Príncipe de Asturias
info
Publisher: American College of Rheumatology
Year of publication: 2017
Type: Conference paper
Sustainable development goals
Abstract
Mechanisms regulating the autoimmune response in rheumatoid arthritis (RA) are not well understood. However, it is known that T CD4+ lymphocytes play a pivotal role initiating and perpetuating the synovial and systemic chronic inflammation found in the disease. Methotrexate (MTX) is the most commonly used Disease-modifying antirheumatic drugs (DMARD) in RA patients. Regrettably, less than thirty percent of these patients do not respond to MTX and need to initiate additional treatments. The potential role of CD4+ T lymphocytes in the MTX clinical response in early RA remains unknown.The objective of this study is to evaluate the relevance of the pattern of IFNγ, IL-4 and IL-17A production by naïve (TN), central memory (TCM), non-terminated effector memory (TNTEM) and terminated effector memory (TTEM) CD4+ T cells for the clinical response to MTX in recently diagnosed DMARD naïve RA patients.